France prompts EMA review of combined oral contraceptives
This article was originally published in Scrip
The European Medicines Agency is looking into whether it is necessary to restrict the use of third and fourth generation combined oral contraceptives to women who cannot take other combined oral contraceptives. The move comes at the behest of French authorities, which have already moved to reduce the use of such products.
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.